Floatz logo

ly4050784

SMARCA4-Deficient Tumor

Eli Lilly and CompanyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the SMARCA4-Deficient Tumor cohort.

Asset / SponsorPhaseRating
Carboplatin
Zhijie Wang
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Eli Lilly and Company
Phase 1CC
Pembrolizumab
Eli Lilly and Company
Phase 1CC

Same molecule, other indications

ly4050784 is also rated in:

Metastatic Solid TumorDormant
C
Indicative ·
37 / 100
View asset →
cancerDormant
C
Indicative ·
36 / 100
View asset →
non-small cell lung carcinomaDormant
C
Indicative ·
36 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →